Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $46.4M (cash outflow) fell 21.9% year over year, behind the -3.0% change in trailing-twelve-month free cash flow. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +21.4% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -21.9% toward the trailing-twelve-month pace of -3.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (206.44M) USD
- Year-over-year change
- -12.8%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (206.44M) | -12.8% |
| FY2024 | 2024-12-31 | (182.94M) | -12.0% |
| FY2023 | 2023-12-31 | (163.4M) | -41.6% |
| FY2022 | 2022-12-31 | (115.41M) | -51.4% |
| FY2021 | 2021-12-31 | (76.24M) | — |
Free Cash Flow vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's LTM Mar 2026 free cash flow of $193.4M is the 4th largest of the 10 companies compared; the peer median is $114.59M.
- Its year-over-year change of -3.0% is the 4th highest of 10, against a peer median of -17.1%.
- Over three fiscal years its annual growth of +21.4% compares with a peer median of +10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $351.8M | +1.4% | +49.8% | 4755.3% |
| LTM Mar 2026 | $291.52M | +2.7% | +36.1% | 314.9% | |
| LTM Mar 2026 | $229.01M | +25.5% | +34.0% | 360.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $193.4M | -3.0% | +21.4% | — |
| LTM Mar 2026 | $130.06M | -17.1% | +3.6% | 147.4% | |
| LTM Mar 2026 | $114.59M | -16.2% | +0.6% | 144.7% | |
| LTM Mar 2026 | $94.78M | -33.7% | +10.3% | 958.1% | |
| LTM Mar 2026 | $81.44M | -37.6% | +14.4% | 140.6% | |
| LTM Mar 2026 | $63.88M | -945.1% | -15.2% | — | |
| LTM Mar 2026 | $38.8M | -77.0% | -9.0% | 55.7% | |
| Peer median (excluding NMRA) | $114.59M | -17.1% | +10.3% | 231.1% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| Deferred Income Tax | (53K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 8.3M | 17.24M | 39.99M | 29.88M |
| Change in Working Capital | (961K) | (6.95M) | (8.9M) | 22.64M | (437K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (759K) | (1.25M) | (581K) | 2.87M | 71K |
| Other Working Capital | (202K) | (5.7M) | (8.32M) | 19.76M | (508K) |
| Other Non-Cash Items | 158.09M | 14.06M | 63.64M | (1.78M) | 841K |
| Operating Cash Flow | (75.42M) | (114.9M) | (163.28M) | (182.94M) | (206.44M) |
| Capital Expenditures | (817K) | (511K) | (117K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (775K) | 0 |
| Purchases of Investments | 0 | (226.37M) | (109.07M) | (312.22M) | (85.8M) |
| Sales of Investments | 0 | 71.87M | 178.17M | 242.44M | 251.17M |
| Other Investing Activities | 0 | (13M) | (4.59M) | 0 | 3.15M |
| Investing Cash Flow | (817K) | (168.01M) | 64.39M | (70.56M) | 168.52M |
| Debt Repayment | 0 | 0 | 0 | 0 | 57.16M |
| Common Stock Issued | 960K | 0 | 233.38M | 13.69M | 19.93M |
| Common Stock Repurchased | 0 | 0 | (491K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.37M | 3.53M | (948K) | 7.91M | 0 |
| Financing Cash Flow | 293.51M | 115.74M | 231.94M | 21.6M | 77.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 217.27M | (167.17M) | 133.05M | (231.89M) | 39.17M |
| Free Cash Flow | (76.24M) | (115.41M) | (163.4M) | (182.94M) | (206.44M) |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.